Barbara Pardini

Dr. Barbara Pardini

Italian Institute for Genomic Medicine - IIGM, c/o FPO IRCCS, 10060 Candiolo (To), Italy
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ATAndrew Thomas
Andrew Thomas
PMPaolo Manghi
Paolo Manghi
Francesco AsnicarFrancesco Asnicar
Francesco Asnicar
Edoardo PasolliEdoardo Pasolli
Edoardo Pasolli
FAFederica Armanini
Federica Armanini
NSNicola Segata
Nicola Segata

3 December 2018 in Nature Genetics
Verified
Journal Article
Open access
JHJeroen R. Huyghe
Jeroen R. Huyghe
SBStephanie A. Bien
Stephanie A. Bien
THTabitha A. Harrison
Tabitha A. Harrison
HKHyun Min Kang
Hyun Min Kang
SCSai Chen
Sai Chen
UPUlrike Peters
Ulrike Peters
To further dissect the genetic architecture of colorectal cancer (CRC), we performed whole-genome sequencing of 1,439 cases and 720 controls, imputed discovered sequence variants and Haplotype Reference Consortium panel variants into genome-wide association study data, and tested for association in 34,869 cases and 29,051 controls. Findings were followed up in an additional 23,262 cases and 38,296 controls. We discovered a strongly protective 0.3% frequency variant signal at CHD1. In a combined meta-analysis of 125,478 individuals, we identified 40 new independent signals at P < 5 × 10-8, bringing the number of known independent signals for CRC to ~100. New signals implicate lower-frequency variants, Krüppel-like factors, Hedgehog signaling, Hippo-YAP signaling, long noncoding RNAs and somatic drivers, and support a role for immune function. Heritability analyses suggest that CRC risk is highly polygenic, and larger, more comprehensive studies enabling rare variant analysis will improve understanding of biology underlying this risk and influence personalized screening strategies and drug development.

20 December 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
Ceres Fernández-RozadillaCeres Fernández-Rozadilla
Ceres Fernández-Rozadilla
MTMaria Timofeeva
Maria Timofeeva
ZCZhishan Chen
Zhishan Chen
PLPhilip Law
Philip Law
MTMinta Thomas
Minta Thomas
UPUlrike Peters
Ulrike Peters

4 October 2007 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
DLDebora Landi
Debora Landi
FGFederica Gemignani
Federica Gemignani
ANAlessio Naccarati
Alessio Naccarati
Barbara PardiniBarbara Pardini
Barbara Pardini
Pavel VodickaPavel Vodicka
Pavel Vodicka
SLStefano Landi
Stefano Landi
Recent evidence indicate that small non-coding RNA molecules, called micro-RNAs (miRNAs), can bind to the 3′ untranslated regions (UTRs) of messenger RNAs and interfere with their translation, thereby regulating cell growth, differentiation, apoptosis and tumorigenesis. Genetic polymorphisms can reside on miRNA-binding sites. Thus, it is conceivable that the miRNA regulation may be affected by polymorphisms on the 3′ UTRs. Since gene deregulation is one of the key mechanisms by which cells can progress to cancer, we hypothesize that common polymorphisms within miRNA-target binding sites could play a role in the individual risk of cancer. In the present study, we selected the 3′ UTRs of 104 genes candidate for colorectal cancer (CRC) and we identified putative miRNA-binding sites by specialized algorithms (PicTar, DianaMicroT, miRBase, miRanda, TargetScan and microInspector). Fifty-seven single-nucleotide polymorphisms (SNPs) were identified in miRNA-binding sites. We evaluated the SNPs for their ability to affect the binding of the miRNA with its target, by assessing the variation of Gibbs free energy between the two alleles of each SNP. We found eight common polymorphisms that were further investigated by a case–control association studies. The study was carried out on a series of cases and controls from Czech Republic, a population with the highest worldwide incidence of CRC. We found statistically significant associations between risk of CRC and variant alleles of CD86 [odds ratio (OR) = 2.74; 95% confidence interval (CI) = 1.24–6.04, for the variant homozygotes] and INSR genes (OR = 1.94; 95% CI = 1.03–3.66, for the variant homozygotes). These results are the first reporting positive association between miRNA-binding SNPs sequences and cancer risk.

14 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Barbara PardiniBarbara Pardini
Barbara Pardini
ASAlexandru-Anton Sabo
Alexandru-Anton Sabo
GBGiovanni Birolo
Giovanni Birolo
George CalinGeorge Calin
George Calin
The last two decades of cancer research have been devoted in two directions: (1) understanding the mechanism of carcinogenesis for an effective treatment, and (2) improving cancer prevention and screening for early detection of the disease. This last aspect has been developed, especially for certain types of cancers, thanks also to the introduction of new concepts such as liquid biopsies and precision medicine. In this context, there is a growing interest in the application of alternative and noninvasive methodologies to search for cancer biomarkers. The new frontiers of the research lead to a search for RNA molecules circulating in body fluids. Searching for biomarkers in extracellular body fluids represents a better option for patients because they are easier to access, less painful, and potentially more economical. Moreover, the possibility for these types of samples to be taken repeatedly, allows a better monitoring of the disease progression or treatment efficacy for a better intervention and dynamic treatment of the patient, which is the fundamental basis of personalized medicine. RNA molecules, freely circulating in body fluids or packed in microvesicles, have all the characteristics of the ideal biomarkers owing to their high stability under storage and handling conditions and being able to be sampled several times for monitoring. Moreover, as demonstrated for many cancers, their plasma/serum levels mirror those in the primary tumor. There are a large variety of RNA species noncoding for proteins that could be used as cancer biomarkers in liquid biopsies. Among them, the most studied are microRNAs, but recently the attention of the researcher has been also directed towards Piwi-interacting RNAs, circular RNAs, and other small noncoding RNAs. Another class of RNA species, the long noncoding RNAs, is larger than microRNAs and represents a very versatile and promising group of molecules which, apart from their use as biomarkers, have also a possible therapeutic role. In this review, we will give an overview of the most common noncoding RNA species detectable in extracellular fluids and will provide an update concerning the situation of the research on these molecules as cancer biomarkers.

27 June 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Barbara PardiniBarbara Pardini
Barbara Pardini
DMDaniela De Maria
Daniela De Maria
AFAntonio Francavilla
Antonio Francavilla
CGCornelia Di Gaetano
Cornelia Di Gaetano
GRGuglielmo Ronco
Guglielmo Ronco
ANAlessio Naccarati
Alessio Naccarati
Invasive cervical cancer (ICC) is caused by high-risk human papillomavirus types (HR-HPVs) and is usually preceded by a long phase of intraepithelial neoplasia (CIN). Before invasion, (epi) genetic changes, potentially applicable as molecular markers within cervical screening, occur in HPV host cells. Epigenetic alterations, such as dysregulation of microRNA (miRNA) expression, are frequently observed in ICC. The mechanisms and role of miRNA dysregulation in cervical carcinogenesis are still largely unknown. We provide an overview of the studies investigating miRNA expression in relation to ICC progression, highlighting their common outcomes and their weaknesses/strengths. To achieve this, we systematically searched through Pubmed database all articles between January 2010 and December 2017. From the 24 studies retrieved, miR-29a and miR-21 are the most frequently down- and up-regulated in ICC progression, respectively. Microarray-based studies show a small overlap, with miR-10a, miR-20b, miR-9, miR-16 and miR-106 found repeatedly dysregulated. miR-34a, miR-125 and miR-375 were also found dysregulated in cervical exfoliated cells in relation to cancer progression. The pivotal role of miRNAs in ICC progression and initial development is becoming more and more relevant. Available studies are essentially based on convenience material, entailing possible selection bias, and frequently of small size: all these points still represent a limitation to a wide comprehension of miRNAs relevant for ICC. The targeted approach instead of a genome-wide investigation still precludes the identification of all the relevant miRNAs in the process. The implementation of deep sequencing on large scale population-based studies will help to discover and validate the relation between altered miRNA expression and CC progression for the identification of biomarkers. Optimally, once explored on a miRNome scale, small specific miRNA signatures maybe used in the context of screening.